Treatment choices and neuropsychological symptoms of a large cohort of early MS
Standard
Treatment choices and neuropsychological symptoms of a large cohort of early MS. / von Bismarck, Olga; Dankowski, Theresa; Ambrosius, Björn; Hessler, Nicole; Antony, Gisela; Ziegler, Andreas; Hoshi, Muna-Miriam; Aly, Lilian; Luessi, Felix; Groppa, Sergiu; Klotz, Luisa; Meuth, Sven G; Tackenberg, Björn; Stoppe, Muriel; Then Bergh, Florian; Tumani, Hayrettin; Kümpfel, Tania; Stangel, Martin; Heesen, Christoph; Wildemann, Brigitte; Paul, Friedemann; Bayas, Antonios; Warnke, Clemens; Weber, Frank; Linker, Ralf A; Ziemann, Ulf; Zettl, Uwe K; Zipp, Frauke; Wiendl, Heinz; Hemmer, Bernhard; Gold, Ralf; Salmen, Anke.
In: NEUROL-NEUROIMMUNOL, Vol. 5, No. 3, 05.2018, p. e446.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treatment choices and neuropsychological symptoms of a large cohort of early MS
AU - von Bismarck, Olga
AU - Dankowski, Theresa
AU - Ambrosius, Björn
AU - Hessler, Nicole
AU - Antony, Gisela
AU - Ziegler, Andreas
AU - Hoshi, Muna-Miriam
AU - Aly, Lilian
AU - Luessi, Felix
AU - Groppa, Sergiu
AU - Klotz, Luisa
AU - Meuth, Sven G
AU - Tackenberg, Björn
AU - Stoppe, Muriel
AU - Then Bergh, Florian
AU - Tumani, Hayrettin
AU - Kümpfel, Tania
AU - Stangel, Martin
AU - Heesen, Christoph
AU - Wildemann, Brigitte
AU - Paul, Friedemann
AU - Bayas, Antonios
AU - Warnke, Clemens
AU - Weber, Frank
AU - Linker, Ralf A
AU - Ziemann, Ulf
AU - Zettl, Uwe K
AU - Zipp, Frauke
AU - Wiendl, Heinz
AU - Hemmer, Bernhard
AU - Gold, Ralf
AU - Salmen, Anke
PY - 2018/5
Y1 - 2018/5
N2 - Objective: To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS.Methods: The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms.Results: Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06-40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0-2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0-377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively.Conclusion: Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.
AB - Objective: To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS.Methods: The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms.Results: Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06-40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0-2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0-377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively.Conclusion: Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.
KW - Journal Article
U2 - 10.1212/NXI.0000000000000446
DO - 10.1212/NXI.0000000000000446
M3 - SCORING: Journal article
C2 - 29511705
VL - 5
SP - e446
JO - NEUROL-NEUROIMMUNOL
JF - NEUROL-NEUROIMMUNOL
SN - 2332-7812
IS - 3
ER -